For type 2 diabetes mellitus. ANDA 206928, held by Aurobindo Pharma. Glipizide.
As of Nov 16, 2026, ANDA 206928 (Glipizide), held by Aurobindo Pharma, was first approved by FDA on May 12, 2017, with 3 approved supplements and 0 published complete response letters.
Glipizide extended-release tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 12, 2017 | Original application | Approved | None posted |
| Mar 13, 2023 | Supplement 10Manufacturing | Approved | None posted |
| Oct 11, 2019 | Supplement 2Labeling · Standard review | Approved | None posted |
| Oct 11, 2019 | Supplement 4Labeling · Standard review | Approved | None posted |
| May 12, 2017 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters